Trials / Unknown
UnknownNCT04249908
Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function
A Non-randomized, Open, Single-dose, Parallel Designed Clinical Study to Evaluate Safety and Pharmacokinetic Characteristics After Oral Administration of Besivo® in Patients With Renal Impairment and Healthy Adult Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of Besifovir and its metabolite, LB80331, in participants with normal and impaired renal function
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Besifovir Dipivoxil Maleate | Besifovir 150 mg q.d. |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2020-09-01
- Completion
- 2021-04-01
- First posted
- 2020-01-31
- Last updated
- 2020-01-31
Source: ClinicalTrials.gov record NCT04249908. Inclusion in this directory is not an endorsement.